|
Healthcare/Hospitals News
Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
Generic Erosion Will Reduce Sales of Schering-Plough's Temodar/Temodal,
the Current Market Leader, According to a New Report from Decision
Resources
WALTHAM, Mass., Dec. 8 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that the approval of agents to treat glioma, most
notably Roche/Genentech/Chugai's Avastin, will drive market sales to more
than double to more than $1.8 billion in 2017 in the United States, France,
Germany, Italy, Spain, the United Kingdom and Japan.
The new Pharmacor report entitled Glioma finds that sales of Avastin,
which is already used off-label to treat relapsed glioma and is in
development for treating both relapsed and newly-diagnosed patients, will
account for more than half of the total market in 2017. Sales of
Schering-Plough's Temodar/Temodal, the current leading agent for glioma in
both patient share and market share, will fall significantly from 2007 to
2017, owing to generic erosion.
According to the report, in addition to Avastin, the launches of
Celldex Therapeutics/Pfizer's CDX-110 and Merck KGaA's cilengitide will
also drive market growth. CDX-110 and cilengitide are being developed for
use in newly diagnosed glioma patients and would each be used in
combination with Temodar/Temodal. Additionally, overall sales for glioma
therapies will be fueled by the launch of AstraZeneca's Recentin, which is
in development for relapsed treatment.
"The treatment of glioma, especially the most malignant
form--glioblastoma multiforme--is largely ineffective, and the prognosis
for these patients is very poor," said Ramya Kollipara, Ph.D. analyst at
Decision Resources. "Considerable opportunity remains in this market as
currently-approved agents provide only modest improvements in patient
outcomes, leaving a high level of unmet need."
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader in
market research publications, advisory services and consulting designed to
help clients shape strategy, allocate resources and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that
offers best-in-class, high-value information and insights on important
sectors of the healthcare industry. Clients rely on this analysis and data
to make informed decisions. Please visit Decision Resources, Inc. at
http://www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
Decision Resources
Christopher Comfort
781-296-2597
ccomfort@dresources.com
Decision Resources, Inc.
Elizabeth Marshall
781-296-2563
emarshall@dresources.com
News Headlines from:
Industry News by Topic... via
PRNewswire
|
